Charles Petersen, MD
Pulmonary Disease · Allentown, PANPI 1285684183
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Johnson & Johnson at 50.1% of the total. Reporting peaked in 2021 at $3,857 and has fallen 96.6% since, to $131 in 2025.
Across 62 payments — averaging $122.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Intuitive Surgical$2K
- Pulmonx Corporation$1K
- GSK$161
- AstraZeneca$153
- Inspire Medical Systems, Inc.$133
- plus $573 from 17 others
Across 1 payment — averaging $3900.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Breas Medical, Inc.$4K
What the payments were for
- Speaking & faculty fees$3,80050%
- Travel & lodging$2,35331%
- Food & beverage$1,40118%
- Education$651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 2 | $3,818 |
| Intuitive Surgical | 9 | $1,512 |
| Pulmonx Corporation | 5 | $1,271 |
| GSK | 10 | $161 |
| AstraZeneca | 11 | $153 |
| Inspire Medical Systems, Inc. | 1 | $133 |
| Lilly USA, LLC | 1 | $113 |
| Genentech USA, Inc. | 5 | $109 |
| Mylan Specialty L.p. | 3 | $56 |
| Harmony Biosciences LLC | 2 | $40 |
| Boston Scientific | 1 | $40 |
| Merck | 1 | $28 |
| Pfizer | 1 | $26 |
| Boehringer Ingelheim | 1 | $21 |
| Sanofi | 1 | $21 |
| Baxter Healthcare | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Circassia Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$3,800
- ZEPHYR ENDOBRONCHIAL VALVE$1,261
- Da Vinci Surgical System$1,080
- DA VINCI SP$253
- CHARTIS CATHETER$140
- ZEPHYR DELIVERY CATHETER$140
- PULMONX CHARTIS TABLET CONSOLE$140
- Inspire$133
- ZEPBOUND$113
How this compares
$7,620 in reported general payments places this provider in the 80th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 17 | $244,570 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 137 | $98,177 |
| Dupixent PenDupilumab | 23 | $86,391 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $26,679 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $25,653 |
| Spiriva RespimatTiotropium Bromide | 24 | $21,605 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $20,275 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $19,585 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $13,680 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 60 | $8,094 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 152 | $5,235 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,519 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,602 |
| Ventolin HfaAlbuterol Sulfate | 41 | $2,590 |
| Modafinil | 28 | $1,220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $40 | $244,57017 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $161 | $144,441239 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $21 | $41,88053 claims |
| AstraZenecaBreztri Aerosphere | $153 | $25,65324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Allentown
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.